{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T15:14:19Z","timestamp":1793200459526,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T00:00:00Z","timestamp":1702252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T00:00:00Z","timestamp":1702252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81871288, 81900636"],"award-info":[{"award-number":["81871288, 81900636"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81871288, 81900636"],"award-info":[{"award-number":["81871288, 81900636"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Key Research and Development Program of China","award":["2022YFC2503300"],"award-info":[{"award-number":["2022YFC2503300"]}]},{"name":"Projects of International Cooperation and Exchanges NSFC","award":["82220108015"],"award-info":[{"award-number":["82220108015"]}]},{"name":"Shandong Provincial Key Research and Development Plan Major Scientific and Technological Innovation Project","award":["2021CXGC011103"],"award-info":[{"award-number":["2021CXGC011103"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>While xanthine oxidase inhibitors target uric acid production, renal urate underexcretion is the predominant subtypes in gout. This study was to compare treatment response to the XOI febuxostat in a gout cohort according to clinical subtypes of hyperuricemia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A prospective cohort study was conducted to compare the efficacy and safety of febuxostat (initially 20\u00a0mg daily, escalating to 40\u00a0mg daily if not at target) in 644 gout patients with the three major clinical subtypes for 12\u00a0weeks. Hyperuricemia was defined as the renal overload subtype, the renal underexcretion subtype, or the combined subtype based on UUE\u2009&gt;\u2009or\u2009\u2264\u2009600\u00a0mg\/d\/1.73 m<jats:sup>2<\/jats:sup> and FE<jats:sub>UA<\/jats:sub>\u2009&lt;\u2009or\u2009\u2265\u20095.5%. The primary endpoint was the rate of achieving serum urate (SU)\u2009&lt;\u20096\u00a0mg\/dL at week 12.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Fewer participants with combined subtype achieved the SU target, 45.5% compared with 64.8% with overload subtype (<jats:italic>P<\/jats:italic>\u2009=\u20090.007), and 56.6% with underexcretion subtype (<jats:italic>P<\/jats:italic>\u2009=\u20090.022). More participants with combined subtype (82%) had febuxostat escalated to 40\u00a0mg than those with overload (62%, <jats:italic>P<\/jats:italic>\u2009=\u20090.001) or underexcretion subtype (68%, <jats:italic>P<\/jats:italic>\u2009=\u20090.001). In all participants, combined subtype hyperuricemia (OR\u2009=\u20090.64, 95%CI 0.41\u20130.99, <jats:italic>P<\/jats:italic>\u2009=\u20090.048) and baseline SU (OR\u2009=\u20090.74, 95%CI 0.62\u20130.89, <jats:italic>P<\/jats:italic>\u2009=\u20090.001) were independently associated with lower rates of achieving SU target.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>People with combined subtype have a lower response to febuxostat, compared to those with either overload or underexcretion subtype. Assessment of hyperuricemia subtype may provide useful clinical data in predicting febuxostat response.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-023-03228-y","type":"journal-article","created":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T10:02:39Z","timestamp":1702288959000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Response to febuxostat according to clinical subtypes of hyperuricemia: a prospective cohort study in primary gout"],"prefix":"10.1186","volume":"25","author":[{"given":"Han","family":"Qi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingshu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Terkeltaub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinde","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixia","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaotong","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Dalbeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changgui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,11]]},"reference":[{"issue":"10287","key":"3228_CR1","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1016\/S0140-6736(21)00569-9","volume":"397","author":"N Dalbeth","year":"2021","unstructured":"Dalbeth N, Gosling AL, Gaffo A, Abhishek A. Gout. Lancet. 2021;397(10287):1843\u201355.","journal-title":"Lancet"},{"key":"3228_CR2","unstructured":"C.M B, R.L W. Kelley and Firestein\u2019s Textbook of Rheumatology (the 10th edition) 1633 (Elsevier, 2017)."},{"issue":"13","key":"3228_CR3","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/00002281-200205000-00015","volume":"14","author":"RL Wortmann","year":"2002","unstructured":"Wortmann RL. Gout and hyperuricemia. Curr Opin Rheumatol. 2002;14(13):281\u20136.","journal-title":"Curr Opin Rheumatol"},{"issue":"66","key":"3228_CR4","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1136\/ard.2008.106856","volume":"69","author":"W Urano","year":"2010","unstructured":"Urano W, Taniguchi A, Anzai N, Inoue E, Kanai Y, Yamanaka M, Endou H, Kamatani N, Yamanaka H. Sodium-dependent phosphate cotransporter type 1 sequence polymorphisms in male patients with gout. Ann Rheum Dis. 2010;69(66):1232\u20134.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"3228_CR5","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/acr.24180","volume":"72","author":"JD FitzGerald","year":"2020","unstructured":"FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, Gelber AC, Harrold LR, Khanna D, King C, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res (Hoboken). 2020;72(6):744\u201360.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"3228_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda-Sanabria J, Coyfish M, Guillo S, Jansen TL, Janssens H, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29\u201342.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"3228_CR7","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1136\/annrheumdis-2017-211574","volume":"77","author":"H Yamanaka","year":"2018","unstructured":"Yamanaka H, Tamaki S, Ide Y, Kim H, Inoue K, Sugimoto M, Hidaka Y, Taniguchi A, Fujimori S, Yamamoto T. Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study. Ann Rheum Dis. 2018;77(2):270\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"3228_CR8","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1111\/1756-185X.14327","volume":"25","author":"K Jatuworapruk","year":"2022","unstructured":"Jatuworapruk K, Dalbeth N. Are we asking the right questions about urate-lowering therapy? Comment on the 2021 Asia-Pacific League of Associations for Rheumatology clinical practice guideline for treatment of gout. Int J Rheum Dis. 2022;25(6):714\u20135.","journal-title":"Int J Rheum Dis"},{"issue":"4","key":"3228_CR9","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/1756-185X.13266","volume":"21","author":"KH Yu","year":"2018","unstructured":"Yu KH, Chen DY, Chen JH, Chen SY, Chen SM, Cheng TT, Hsieh SC, Hsieh TY, Hsu PF, Kuo CF, et al. Management of gout and hyperuricemia: multidisciplinary consensus in Taiwan. Int J Rheum Dis. 2018;21(4):772\u201387.","journal-title":"Int J Rheum Dis"},{"issue":"2","key":"3228_CR10","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/j.1440-1797.2010.01368.x","volume":"16","author":"HJ Shin","year":"2011","unstructured":"Shin HJ, Takeda M, Enomoto A, Fujimura M, Miyazaki H, Anzai N, Endou H. Interactions of urate transporter URAT1 in human kidney with uricosuric drugs. Nephrology (Carlton). 2011;16(2):156\u201362.","journal-title":"Nephrology (Carlton)"},{"issue":"2","key":"3228_CR11","doi-asserted-by":"publisher","first-page":"e00291","DOI":"10.1002\/prp2.291","volume":"5","author":"AK Mandal","year":"2017","unstructured":"Mandal AK, Mercado A, Foster A, Zandi-Nejad K, Mount DB. Uricosuric targets of tranilast. Pharmacol Res Perspect. 2017;5(2):e00291.","journal-title":"Pharmacol Res Perspect"},{"issue":"1","key":"3228_CR12","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1124\/jpet.119.259341","volume":"371","author":"T Taniguchi","year":"2019","unstructured":"Taniguchi T, Ashizawa N, Matsumoto K, Saito R, Motoki K, Sakai M, Chikamatsu N, Hagihara C, Hashiba M, Iwanaga T. Pharmacological evaluation of dotinurad, a selective urate reabsorption inhibitor. J Pharmacol Exp Ther. 2019;371(1):162\u201370.","journal-title":"J Pharmacol Exp Ther"},{"issue":"9","key":"3228_CR13","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1136\/ard.57.9.545","volume":"57","author":"F Perez-Ruiz","year":"1998","unstructured":"Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, Herrero-Beites A, Garcia-Erauskin G, Ruiz-Lucea E. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis. 1998;57(9):545\u20139.","journal-title":"Ann Rheum Dis"},{"key":"3228_CR14","doi-asserted-by":"publisher","first-page":"806710","DOI":"10.3389\/fmed.2021.806710","volume":"8","author":"X Xue","year":"2021","unstructured":"Xue X, Yuan X, Han L, Li X, Merriman TR, Cui L, Liu Z, Sun W, Wang C, Yan F, et al. Effect of clinical typing on serum urate targets of benzbromarone in Chinese gout patients: a prospective cohort study. Front Med (Lausanne). 2021;8:806710.","journal-title":"Front Med (Lausanne)"},{"issue":"7","key":"3228_CR15","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.3899\/jrheum.101156","volume":"38","author":"DS Goldfarb","year":"2011","unstructured":"Goldfarb DS, MacDonald PA, Hunt B, Gunawardhana L. Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors. J Rheumatol. 2011;38(7):1385\u20139.","journal-title":"J Rheumatol"},{"key":"3228_CR16","doi-asserted-by":"crossref","unstructured":"Yan F, Xue X, Lu J, Dalbeth N, Qi H, Yu Q, Wang C, Sun M, Cui L, Liu Z et al. Superiority of low-dose benzbromarone to low-dose febuxostat in a prospective, randomized comparative effectiveness trial in gout patients with renal uric acid underexcretion. Arthritis Rheumatol. 2022;74(12):2015\u201323.","DOI":"10.1002\/art.42266"},{"issue":"1","key":"3228_CR17","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1136\/annrheumdis-2013-203779","volume":"74","author":"P Richette","year":"2015","unstructured":"Richette P, Clerson P, Perissin L, Flipo RM, Bardin T. Revisiting comorbidities in gout: a cluster analysis. Ann Rheum Dis. 2015;74(1):142\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"3228_CR18","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1093\/rheumatology\/key096","volume":"57","author":"M Bevis","year":"2018","unstructured":"Bevis M, Blagojevic-Bucknall M, Mallen C, Hider S, Roddy E. Comorbidity clusters in people with gout: an observational cohort study with linked medical record review. Rheumatology (Oxford). 2018;57(8):1358\u201363.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"3228_CR19","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1002\/oby.22202","volume":"26","author":"H Nagao","year":"2018","unstructured":"Nagao H, Nishizawa H, Tanaka Y, Fukata T, Mizushima T, Furuno M, Bamba T, Tsushima Y, Fujishima Y, Kita S, et al. Hypoxanthine secretion from human adipose tissue and its increase in hypoxia. Obesity (Silver Spring). 2018;26(7):1168\u201378.","journal-title":"Obesity (Silver Spring)"},{"issue":"5","key":"3228_CR20","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1007\/s11695-019-04328-y","volume":"30","author":"C Lu","year":"2020","unstructured":"Lu C, Li Y, Li L, Kong Y, Shi T, Xiao H, Cao S, Zhu H, Li Z, Zhou Y. Alterations of serum uric acid level and gut microbiota after Roux-en-Y gastric bypass and sleeve gastrectomy in a hyperuricemic rat model. Obes Surg. 2020;30(5):1799\u2013807.","journal-title":"Obes Surg"},{"issue":"6887","key":"3228_CR21","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/nature742","volume":"417","author":"A Enomoto","year":"2002","unstructured":"Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, Hosoyamada M, Takeda M, Sekine T, Igarashi T, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature. 2002;417(6887):447\u201352.","journal-title":"Nature"},{"issue":"7","key":"3228_CR22","doi-asserted-by":"publisher","first-page":"499","DOI":"10.7326\/0003-4819-143-7-200510040-00009","volume":"143","author":"HK Choi","year":"2005","unstructured":"Choi HK, Mount DB, Reginato AM. American College of P, American Physiological S: Pathogenesis of gout. Ann Intern Med. 2005;143(7):499\u2013516.","journal-title":"Ann Intern Med"},{"issue":"10","key":"3228_CR23","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1136\/annrheumdis-2015-208237","volume":"74","author":"T Neogi","year":"2015","unstructured":"Neogi T, Jansen T, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, Brown M, Choi H, Edwards NL, Janssens H. 2015 Gout classification criteria. Ann Rheum Dis. 2015;74(10):1789\u201398.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"3228_CR24","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1007\/s11255-020-02754-x","volume":"53","author":"F Li","year":"2021","unstructured":"Li F, Guo H, Zou J, Fu C, Liu S, Xiao J, Ye Z. Clinical classification of hyperuricemia in patients with chronic kidney disease. Int Urol Nephrol. 2021;53(8):1665\u201374.","journal-title":"Int Urol Nephrol"},{"issue":"11","key":"3228_CR25","doi-asserted-by":"publisher","first-page":"e0224680","DOI":"10.1371\/journal.pone.0224680","volume":"14","author":"Y Wang","year":"2019","unstructured":"Wang Y, Chen C, Yan Y, Yuan Y, Wang KK, Chu C, Hu JW, Ma Q, Liao YY, Fu BW, et al. Association of uric acid in serum and urine with subclinical renal damage: Hanzhong Adolescent Hypertension Study. PLoS ONE. 2019;14(11):e0224680.","journal-title":"PLoS ONE"},{"issue":"4","key":"3228_CR26","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1272\/jnms.JNMS.2022_89-401","volume":"89","author":"T Yamada","year":"2022","unstructured":"Yamada T, Kashiwagi T, Sakai Y. Effects of renal function on urinary excretion and serum concentration of uric acid in patients treated with febuxostat for chronic kidney disease. J Nippon Med Sch. 2022;89(4):360\u20137.","journal-title":"J Nippon Med Sch"},{"issue":"5","key":"3228_CR27","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1002\/art.33483","volume":"64","author":"AL Gaffo","year":"2012","unstructured":"Gaffo AL, Schumacher HR, Saag KG, Taylor WJ, Dinnella J, Outman R, Chen L, Dalbeth N, Sivera F, Vazquez-Mellado J, et al. Developing a provisional definition of flare in patients with established gout. Arthritis Rheum. 2012;64(5):1508\u201317.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"3228_CR28","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1080\/15257770.2011.596496","volume":"30","author":"H Yamanaka","year":"2011","unstructured":"Yamanaka H. Japanese Society of G, Nucleic Acid M: Japanese guideline for the management of hyperuricemia and gout: second edition. Nucleosides Nucleotides Nucleic Acids. 2011;30(12):1018\u201329.","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"1","key":"3228_CR29","first-page":"83","volume":"15","author":"BF Zhou","year":"2002","unstructured":"Zhou BF. Cooperative Meta-Analysis Group of the Working Group on Obesity in C: Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults\u2013study on optimal cut-off points of body mass index and waist circumference in Chinese adults. Biomed Environ Sci. 2002;15(1):83\u201396.","journal-title":"Biomed Environ Sci"},{"key":"3228_CR30","unstructured":"Metabolic Syndrome Research Group of Chinese Diabetes Society. Recommendations on metabolic syndrome of Chinese diabetes Society. Chin J Diabetes. 2004;12(003):156\u2013161."},{"issue":"3","key":"3228_CR31","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.amjcard.2005.03.085","volume":"96","author":"T McLaughlin","year":"2005","unstructured":"McLaughlin T, Reaven G, Abbasi F, Lamendola C, Saad M, Waters D, Simon J, Krauss RM. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? Am J Cardiol. 2005;96(3):399\u2013404.","journal-title":"Am J Cardiol"},{"key":"3228_CR32","doi-asserted-by":"crossref","unstructured":"Yanai H, Adachi H, Hakoshima M, Katsuyama H. Molecular biological and clinical understanding of the pathophysiology and treatments of hyperuricemia and its association with metabolic syndrome, cardiovascular diseases and chronic kidney disease. Int J Mol Sci. 2021;22(17):9221.","DOI":"10.3390\/ijms22179221"},{"issue":"11","key":"3228_CR33","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1002\/art.41779","volume":"73","author":"N McCormick","year":"2021","unstructured":"McCormick N, O\u2019Connor MJ, Yokose C, Merriman TR, Mount DB, Leong A, Choi HK. Assessing the causal relationships between insulin resistance and hyperuricemia and gout using bidirectional Mendelian randomization. Arthritis Rheumatol. 2021;73(11):2096\u2013104.","journal-title":"Arthritis Rheumatol"},{"key":"3228_CR34","doi-asserted-by":"publisher","first-page":"518","DOI":"10.3389\/fphar.2016.00518","volume":"7","author":"H Miyata","year":"2016","unstructured":"Miyata H, Takada T, Toyoda Y, Matsuo H, Ichida K, Suzuki H. Identification of febuxostat as a new strong ABCG2 inhibitor: potential applications and risks in clinical situations. Front Pharmacol. 2016;7:518.","journal-title":"Front Pharmacol"},{"key":"3228_CR35","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/ncomms1756","volume":"3","author":"K Ichida","year":"2012","unstructured":"Ichida K, Matsuo H, Takada T, Nakayama A, Murakami K, Shimizu T, Yamanashi Y, Kasuga H, Nakashima H, Nakamura T, et al. Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat Commun. 2012;3:764.","journal-title":"Nat Commun"},{"issue":"5","key":"3228_CR36","doi-asserted-by":"publisher","first-page":"9149","DOI":"10.3390\/ijms15059149","volume":"15","author":"D Zhou","year":"2014","unstructured":"Zhou D, Liu Y, Zhang X, Gu X, Wang H, Luo X, Zhang J, Zou H, Guan M. Functional polymorphisms of the ABCG2 gene are associated with gout disease in the Chinese Han male population. Int J Mol Sci. 2014;15(5):9149\u201359.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"3228_CR37","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1093\/rheumatology\/kex467","volume":"57","author":"MC Wallace","year":"2018","unstructured":"Wallace MC, Roberts RL, Nanavati P, Miner JN, Dalbeth N, Topless R, Merriman TR, Stamp LK. Association between ABCG2 rs2231142 and poor response to allopurinol: replication and meta-analysis. Rheumatology (Oxford). 2018;57(4):656\u201360.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"3228_CR38","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1093\/rheumatology\/key423","volume":"58","author":"LK Stamp","year":"2019","unstructured":"Stamp LK, Topless R, Miner JN, Dalbeth N, Merriman T. No association between ATP-binding cassette transporter G2 rs2231142 (Q141K) and urate-lowering response to febuxostat. Rheumatology (Oxford). 2019;58(3):547\u20138.","journal-title":"Rheumatology (Oxford)"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-023-03228-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-023-03228-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-023-03228-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T22:03:44Z","timestamp":1702332224000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-023-03228-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,11]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3228"],"URL":"https:\/\/doi.org\/10.1186\/s13075-023-03228-y","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,11]]},"assertion":[{"value":"10 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the Affiliated Hospital of Qingdao University and registered in Chinese Clinical Trial Registration Center (#ChiCTR2100043573). Written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"241"}}